SCHEMBL2863751

SCHEMBL2863751

CC(O)c1ccc(-c2cccc(Nc3cc(CCO)ccn3)n2)s1

nearest known ligand 0.42

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
KARS1 Q15046 9/20 0.42
SYK P43405 5/20 0.36
TYK2 P29597 1/20 0.36
KDR P35968 2/20 0.33
NR3C2 P08235 2/20 0.33
AKT3 Q9Y243 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2862687 0.87 KARS1 (0.41) KARS1SYKTYK2KDR
SCHEMBL2862437 0.84 KARS1 (0.53) KARS1SYKKDR
SCHEMBL13136541 0.84 KARS1 (0.53) KARS1SYKKDR
SCHEMBL13136579 0.81 KARS1 (0.42) KARS1SYKTYK2KDRNR3C2
SCHEMBL14390796 0.80 KARS1 (0.39) KARS1SYKTYK2KDR
SCHEMBL13136578 0.77 KARS1 (0.54) KARS1SYKKDR
SCHEMBL13136572 0.75 KARS1 (0.51) KARS1SYKKDR
SCHEMBL13136574 0.74 KARS1 (0.51) KARS1SYKKDR
SCHEMBL13136616 0.73 KARS1 (0.56) KARS1SYKKDR
SCHEMBL13136623 0.72 KARS1 (0.41) KARS1SYKTYK2KDRAKT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1854793-A1 NOVEL AMINOPYRIDINE COMPOUND WITH Syk INHIBITORY ACTIVITY Japan Tobacco, Inc. (JP) 2007-11-14 EP claimed
US-20060205731-A1 Novel aminopyridine compounds having Syk inhibitory activity JAPAN TOBACCO INC. (JP) 2006-09-14 US claimed
US-7803801-B2 Aminopyridine compounds having Syk inhibitory activity JAPAN TOBACCO, INC. (JP) 2010-09-28 US disclosed
US-7803801-B2 Aminopyridine compounds having Syk inhibitory activity JAPAN TOBACCO, INC. (JP) 2010-09-28 US disclosed
US-7803801-B2 Aminopyridine compounds having Syk inhibitory activity JAPAN TOBACCO, INC. (JP) 2010-09-28 US disclosed
EP-1854793-A1 NOVEL AMINOPYRIDINE COMPOUND WITH Syk INHIBITORY ACTIVITY Japan Tobacco, Inc. (JP) 2007-11-14 EP disclosed
EP-1854793-A1 NOVEL AMINOPYRIDINE COMPOUND WITH Syk INHIBITORY ACTIVITY Japan Tobacco, Inc. (JP) 2007-11-14 EP disclosed
US-20060205731-A1 Novel aminopyridine compounds having Syk inhibitory activity JAPAN TOBACCO INC. (JP) 2006-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060205731-A1 Novel aminopyridine compounds having Syk inhibitory activity SYK, BTK, ZAP70 KARS1 2175/4885SYK 1/4885TYK2 41/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.